Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Steele

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Clinical and Experimental Immunology|August 11, 2023
Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19Rohan Ameratunga, Emily Mears, Euphemia Leung, et al.
Expert Review of Clinical Immunology|April 1, 2021
Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infectionRohan Ameratunga, See-Tarn Woon, Richard Steele, et al.
Clinical & Translational Immunology|November 9, 2017
Epistatic interactions between mutations of TACI (<i>TNFRSF13B</i>) and <i>TCF3</i> result in a severe primary immunodeficiency disorder and systemic lupus erythematosusRohan Ameratunga, Wikke Koopmans, See-Tarn Woon, et al.
The New Zealand Medical Journal|May 22, 2020
Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infectionRohan Ameratunga, Klaus Lehnert, Euphemia Leung, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Clinical and Experimental Immunology|August 11, 2023
Soluble wild-type ACE2 molecules inhibit newer SARS-CoV-2 variants and are a potential antiviral strategy to mitigate disease severity in COVID-19Rohan Ameratunga, Emily Mears, Euphemia Leung, et al.
Expert Review of Clinical Immunology|April 1, 2021
Perspective: the nose and the stomach play a critical role in the NZACE2-Pātari* (modified ACE2) drug treatment project of SARS-CoV-2 infectionRohan Ameratunga, See-Tarn Woon, Richard Steele, et al.
Clinical & Translational Immunology|November 9, 2017
Epistatic interactions between mutations of TACI (<i>TNFRSF13B</i>) and <i>TCF3</i> result in a severe primary immunodeficiency disorder and systemic lupus erythematosusRohan Ameratunga, Wikke Koopmans, See-Tarn Woon, et al.
The New Zealand Medical Journal|May 22, 2020
Inhaled modified angiotensin converting enzyme 2 (ACE2) as a decoy to mitigate SARS-CoV-2 infectionRohan Ameratunga, Klaus Lehnert, Euphemia Leung, et al.
Pageof 6